Corline Biomedical AB Company Description

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound.

The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries.

The company was incorporated in 1991 and is based in Uppsala, Sweden.

Corline Biomedical AB

Country	Sweden
Founded	1991
Industry	Biotechnology
Sector	Healthcare
Employees	13
CEO	Henrik Nittmar

Contact Details

Address: Lefflersgatan 5 Uppsala, 754 50 Sweden
Phone	46 18 71 30 90
Website	corline.se

Stock Details

Ticker Symbol	CLBIO
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0006887451
SIC Code	2836

Key Executives

Name	Position
Dr. Henrik Nittmar Ph.D.	Chief Executive Officer
Asa Holm	Chief Operating Officer